sCD30 and sCD40L detection in patients with osteosarcoma, chondrosarcoma and Ewing sarcoma

Area of Science:

• Oncology
• Immunology
• Biochemistry

Background:

• Primary malignant bone tumors affect children and adolescents, with Osteosarcoma, Ewing sarcoma, and chondrosarcoma being most common.
• Elevated soluble CD30 (sCD30) and soluble CD40 ligand (sCD40L) are noted in lymphoma, leukemia, and autoimmune disorders.

Purpose of the Study:

• To investigate serum concentrations of sCD30 and sCD40L in patients diagnosed with primary malignant bone tumors.

Main Methods:

• Enzyme-linked immunosorbent assay (ELISA) was used to measure serum sCD30 and sCD40L levels.
• The study included 54 patients with primary bone tumors (31 Osteosarcomas, 14 Ewing sarcomas, 9 Chondrosarcomas) and 54 healthy controls.
• Patients with prior treatment history were excluded.

Main Results:

• Mean serum sCD30 was significantly higher in Ewing sarcoma patients compared to controls (p=0.007).
• Mean serum sCD40L was significantly elevated in Osteosarcoma, Ewing sarcoma, and Chondrosarcoma patients versus controls (p<0.0001).
• Chondrosarcoma patients exhibited higher sCD40L levels than both Ewing sarcoma and Osteosarcoma patients (p<0.001).

Conclusions:

• Serum sCD30 and sCD40L levels show an increase in primary bone tumors.
• The diagnostic or prognostic significance of these elevated markers requires further research.